# Tanzi to receive $41m for Alzheimer’s research

> Neuroscientist Rudolph Tanzi gets $41m federal grant to test Alzheimer’s drug combinations.
- Title: Tanzi to receive $41m for Alzheimer’s research | Shortify
- Summary: Neuroscientist Rudolph Tanzi gets $41m federal grant to test Alzheimer’s drug combinations. Rudolph Tanzi, a neuroscientist at Mass General Brigham, will…
- Keywords: rudolph tanzi, mass general brigham, alzheimer's disease, drug combinations, federal grants, clinical trials, news, local, Tanzi, receive, 41m, Alzheimer
- Source: The Boston Globe — https://bostonglobe.com/2026/10/21/business/alzheimers-prevention-mass-general-brigham
- Read time: 1 min
- Topics: rudolph tanzi, mass general brigham, alzheimer's disease, drug combinations, federal grants, clinical trials, news, local
## MGB neuroscientist gets $41m grant
Rudolph Tanzi, a neuroscientist at Mass General Brigham, will receive up to $41 million in federal health grants to fund a four-year study testing drug combinations for Alzheimer’s.

> Everything’s coming to fruition
## Additional $25m from philanthropists
Tanzi’s research team also receives $25 million from philanthropists to support clinical trials for experimental Alzheimer’s treatments.
## Acta Pharmaceuticals raises $24m
Acta Pharmaceuticals, a biotech company co-founded by Tanzi, raised $24 million in seed financing to begin a clinical trial of an experimental Alzheimer’s drug.
## Tanzi’s drug screening approach
Tanzi’s team screened 2,000 approved drugs and 4,000 natural compounds to identify five to ten potential drug combinations for Alzheimer’s.
## Clinical trial design
The trial will test five drug combinations on 300 patients with Alzheimer’s biomarkers, using placebo groups to measure disease progression.
## Tanzi’s vision for prevention
Tanzi hopes daily pills could block Alzheimer’s buildup before cognitive decline, similar to how statins prevent heart disease.
## Key takeaway

Rudolph Tanzi, a neuroscientist at Mass General Brigham, will receive $41 million in federal grants to test five to ten drug combinations for Alzheimer’s disease.